Global Views
   Middle East & Africa
 Embassy News
 Arts & Living
 Travel & Hotel
 Medical Tourism New
 Letters to Editor
 Photo Gallery
 News Media Link
 TV Schedule Link
 News English
 Hospitals & Clinics
 Flea Market
 Moving & Packaging
 Religious Service
 Korean Classes
 Korean Weather
 Real Estate
 Home Stay
 Room Mate
 English Teaching
 Job Offered/Wanted
 Hotel Lounge
 Foreign Exchanges
 Korean Stock
 Business Center
 PR & Ads
 Arts & Performances
 Restaurants & Bars
 Tour & Travel
 Shopping Guide
 Foreign Missions
 Community Groups
 Foreign Workers
 Useful Services
 ST Banner Exchange
New TB Treatment Breakthroughs Must Reach the Needy without Delay
Special Contribution
By Shobha Shukla
A tuberculosis (TB) patient
Recently, results of a large-scale phase-3 study of a potentially game-changing TB treatment therapy were announced that give us enormous hope that shorter, all-oral (no injectables), more effective and less toxic treatments will reach those in-need globally without any delay.

Earlier, treatment for drug-resistant forms of TB lasted for 20 to 24 months duration or more, and treatment success rate hovered around 50% or less, with very high rates of drug toxicities and side effects. But this new six months therapy (of BPaL - Bedaquiline, Pretomanid and Linezolid) shows that treatment success rate can be over 90%.

With less than 100 months left to end TB globally (and less than 40 months left to end TB in India), there is no doubt that we need more effective and less toxic treatments to cure TB, which continues to be among the top deadly infectious diseases today. It is therefore imperative that game-changing scientific breakthroughs must translate into public health gains in terms of reduced human suffering and deaths related to TB.

Shorter and more effective treatment for drug-resistant TB

Science has proven that it is possible to reduce the duration of treatment of highly drug-resistant forms of TB from around 2 years to 6 months, reduce the toxic side effects of the medicines and significantly improve treatment outcomes.

But first, let us understand why do we need new medicines and why do older medicines stop being affective against disease-causing germs, such as, TB bacteria? Antimicrobial resistance, also known as drug resistance, makes an infectious agent (such as the TB causing bacteria) resistant to medicines. So, when TB bacteria become resistant to a medicine, they cannot be killed by it. That is why we need a different combination of medicines (to which the bacteria are sensitive) to treat the disease. Choice of medicines to treat is limited, treatment is long, risk of severe illness and dying is high, and a host of other issues, like drug toxicity, side effects, and even post-treatment disabilities at times, are other challenges.

But there is good news too. Thanks to rigorous scientific research, we have shorter, safer, and more effective therapies for treating drug-resistant TB now.

Watershed moment in TB treatment science

The final phase-3 results of the ZeNix study were published in New England Journal of Medicine which show that BPaL treatment regimen consisting of three medicines - Bedaquiline, Pretomanid, and Linezolid - is not only highly effective against drug-resistant forms of TB, but this high effectiveness can also be maintained with reduction in dosing and/or duration of Linezolid. Reduction in dosing and duration of Linezolid means people on this therapy faced less Linezolid-related side-effects - so treatment becomes more tolerable.

This ZeNix study was led by TB Alliance and took place in eleven sites across Georgia, Moldova, Russia, and South Africa.

Why ZeNix study results are important and build upon the evidence of previously done Nix-TB study?

The Nix-TB Study results, which were published in New England Journal of Medicine in 2020, had shown very high treatment success rate of over 90% when all-oral BPaL treatment regimen was used for six months to treat drug-resistant forms of TB. But the Linezolid-related side effects were very alarming.

High treatment effectiveness of BPaL regimen in Nix-TB study “came at the cost with very high rates of toxicity - 81% of the patients, who had one or more episodes of peripheral neuropathy, required the regimen to be either dose-adjusted, interrupted or abandoned altogether, and 48% of participants experienced one or more episode of myelosuppression so a reduction in haemoglobin (red blood cells), white blood cells or platelets,” said Dr Conor Tweed, Honorary Clinical Lecturer, Medical Research Council, Clinical Trials Unit at University College London (UCL), who was in conversation with CNS. Jessica Wiggs, Senior Communication Specialist of TB Alliance also joined the conversation.

That is why ZeNix Study was conducted to check if Linezolid related side effects could be reduced with reduced Linezolid dosing and/or duration of therapy, and how this would impact the effectiveness of the BPaL regimen.

In ZeNix study, there were four groups of people, all of whom had drug-resistant forms of TB, and who were treated using the all oral, six months long BPaL regimen of Bedaquiline, Pretomanid and Linezolid. The only difference between these four groups was in the duration and/or dosing of Linezolid.

The first group received 1200mg of Linezolid for six months; second group received 1200mg of Linezolid for two months; third group received 600mg of Linezolid for six months, and the fourth group received 600mg of Linezolid for two months, shared Dr Tweed.

Overall treatment efficacy across the four groups ranged between 93% and 84% - with 93% among those who received 1200mg of Linezolid for six months and 84% among those who received 600mg of Linezolid for two months. It is important to note that the group with 600mg of Linezolid for six months had 91% efficacy – very similar to the highest efficacy of 93% - but drastically reduced levels of Linezolid-related toxicity - such as peripheral neuropathy which was reported in only 24%, and myelosuppression reported in only 2% patients in the study.

Dr Tweed shared that this study had had a life influencing impact on those enrolled. There were 181 people who took part in ZeNix study (about 20% of them in each of the four groups were people living with HIV). All of them had highly drug-resistant TB - a form of TB that previously required 20 to 24 months to treat with associated cure rates between 40-50% in the field, and alarmingly high rates of toxicity. This study demonstrated that treatment success rate with the all oral BPaL regimen was over 90%, treatment duration was reduced to one-fourth of the previous regimen (6 months compared to 20-24 months), and much reduced drug-related toxicities. There is still work to be done for even better treatments.

The BPaL regimen to treat highly drug resistant forms of TB has been endorsed by the UN health agency, the World Health Organization (WHO) for use under operational research conditions. Earlier, United States FDA and European regulators had already given the green signal for the use of this regimen. Recently the Indian regulators have also given a thumbs up to Pretomanid and shorter regimens.

However, we have to remember that the number of participants in ZeNix study was relatively small, given the burden of TB in the real world. Dr Conor cautioned that “we do not think we feel comfortable making a definitive casual statement about the relationship between the different doses of Linezolid and the incidence of toxicity, but I think we would feel confident to draw attention to the association between higher rates of toxicity with the higher doses of Linezolid.”

He added that “it is unacceptable for people to die from an infection that could theoretically be treated”.

TB could also be prevented as we have the tools to prevent TB but are failing to do so because of which over 10 million people suffer from active TB disease every year.

As this study was done on those with drug resistant forms of TB of the lungs (and not extrapulmonary TB), Dr Tweed remarked that it was done so, as TB of the lungs (pulmonary TB) is easier to diagnose, monitor, and confirm cure. Also three out of four TB patients suffer from TB of the lungs.

Larger goal

The larger goal is to have many novel TB treatment regimens, which can be tailored as per the drug resistance profile of a person (individualised therapy), said Dr Tweed.

But we have to tread with caution as many drugs developed in the past century have lost their efficacy due to drug resistance. Sadly, resistance to the relatively new wonder drug Bedaquiline is already getting reported from South Africa, for instance.

“There is no such thing as a magic bullet when we are dealing with drug resistance. Any novel regimen has to be taken with the perspective of programmatic adjustments of what is needed. Moreover, there needs to be a big increase in funding for TB programming in the most hard-hit areas. We also need to see an improvement in TB diagnostics - not just in developing new technology, but also in its rollout. We need to see better awareness and we do need global development cooperation to make this work,” said Dr Tweed.

Governments worldwide have promised to end TB globally by 2030. With less than 100 months left to deliver on these goals, let us hope that this public health and human rights urgency will spur us all towards judicious use of all the novel and effective TB treatments, and fully invest in TB programming so that no one is left behind when it comes to preventing TB, diagnosing TB early, treating TB with effective medicines, ensuring cure and providing the full spectrum of care and support, given the local realities.

Related Articles
    Are We Prepared to Combat Online Gender-based ...
    Shooting Our Own Foot: Misuse of Medicines Is ...
    When Will We Start Caring for Our Caregivers?
    Ending TB One Barangay at a Time
    Are We Putting Money Where the Mouth Is to ...
    Early and Accurate TB Diagnosis Is the Gateway ...
    Long Walk to Transgender Rights and Gender ...
    Strong Local Actions Are Pivotal to Reduce ...
    The Head Must Follow What the Hand Writes
    Ending Tobacco Smoking Is Bedrock for ...
    Asia Pacific Has over 6.7 Million New TB Cases
    Will Shorter, Safer and More Effective TB ...
    Whither Women's Reproductive Health in Asia ...
    Build the World We Want: Healthy Future for All
    How Will Children Living with HIV Grow Up ...
    Writing Is on the Wall: Pictorial Health ...
    Failing on the Basics: Are We Able to Break ...
    A Bouquet of Novel Compounds: New Treatment ...
    One Size Does Not Fit All: Expanding the ...
    Tale of Two Pandemics: Follow the Science and ...
    Governments Must Adopt a Strong Political ...
    What Is the Ring?
    Disability Is Not Limited to the Body, It Is ...
    Accelerating Progress on Sexual & Reproductive ...
    Stop This Shaming of Menstruation
    Complacency Breeds Failure: Consolidate ...
    For Age Is Opportunity No Less Than Youth ...
    New Study Pegs the Number of TB Cases in India ...
    Self-stigma: Let Us Do More Than Just "Ttalk ...
    We Cannot Eliminate TB If We Leave Children ...
    MDR-TB Treatment Rgimen: Short Indeed Is ...
    A Plain Face Can Take the Sheen Out of Deadly ...
    Strike at the Root of the Problem to Kill TB
    Antibiotic Use Is Driving Antibiotic Resistance
    Big Push for Transgender and Hijra Welfare
    Where There Is a Will There Is a Way: Teeja ...
    Lung Cancer: Difficult to Diagnose, Difficult ...
    Long Road to Justice: Human Rights of Female ...
    Medical Malpractices: Is There Light at the ...
    Overcoming Roadblocks in Translating ...
    Management of Respiratory Diseases beyond ...
    Gender Justice to Be at the Heart of ...
    Connecting the Dots: Tobacco Use, Diabetes, ...
    It Is Time To Control Asthma
    Call for No More New HIV Infected Children
    Smoking Goes Electronic
    Break the Silence around Cancer
    How Can You Treat Your Illness Unless You Take ...
    Asthma Medicines Still Unaffordable for Many
    New Technique to Prevent Diabetic Lower-Limb ...
    Cycle Beads: The Bead String for Family ...
    Beware: All Forms of Tobacco Are Harmful!
    Mother's Milk Is the Best Nutrition for the ...
    Where Is The TB Quilt, Nay Mask?
    Hello, This Is Nature’s Call From Garbage ...
    Tuberculosis: Ugly Scar on Beautiful Childhood
    Towards A More Enabling Environment for ...
    What’s Cooking in Kitchen: Peace or Conflict?
    Feed Your Child Well: Prevent Pneumonia
    Costly Medicines Mean Debt or Death for People ...
    AIDS Epidemic at a Critical Juncture in ...
    Watch Your Tongue Mr. Minister!
    Free Trade Agreements: A Threat To People's ...
    In The Pursuit Of Healthy Happiness
    Empowering Rural Women
    Say Yes To Life: Say No To Tobacco
    Homophobia Is A Human Rights Issue
    Viva La Woman Power
    Rubbish Rubbish Food and Embrace Healthy ...
    Of Music and Divinity
    Wake Up Call on Childhood Obesity after Years ...
    A New Hope of Life for Our Ailing Education ...
    Reminiscences of Egypt
    Do Not Break the Nucleus
    Whispers of Sanity in the Frenzy of Madness
    Tobacco Cessation Can Piggy-back Ride on ...
    In The Spirit Of Freedom (from Tobacco)
    World Conference on Tobacco or Health to ...
    Requiem for Purity
    Rhapsody 2008 -- a Symphony of Different ...
    'Diabetes Doctor Is at Your Doorstep' in ...
    Activists Decry India's Deferment of Pictorial ...
    South-East Asian Diabetes Summit to Open Up in ...
    Special on Universal Children's Day
    The Wrath Of God
    World Food Scarcity and the Challenges of ...
    Victim of Terrorism -- the Common Man
    Teachers' Day: The Sacrificial Goat
    Hiroshima Day: Let Us Worship Peace and Shun ...
    Whither the Innocence of Childhood?
    Food for Thought -- on World Food Day
    Love Is the Missing Link in War-on-Terror
    Irom Sharmila: The Iron Lady
    India Poised And Shining
    Is It Just Another Day in Life of Indian Woman?
    He Has His Cake and Eats It Too
    To Be Young, to Be Married, and to Be in India
    The Mad Mad World of Ads

Other Articles by Shobha Shukla
    Are We Prepared to Combat Online ...
    When Will We Start Caring for Our Caregivers?
    Ending TB One Barangay at a Time
    Are We Putting Money Where the Mouth Is to ...
    Long Walk to Transgender Rights and Gender ...

Ms. Shobha Shukla has been teaching physics at India's noted Loreto Convent, and has written for The Hindustan Times and Women's Era in the past. She serves as editor of Citizen News Service (CNS). She can be contacted at






The Seoul Times, Shinheung-ro 36ga-gil 24-4, Yongsan-gu, Seoul, Korea 04337 (ZC)
Office: 82-10-6606-6188 Publisher & Editor: Joseph Joh
Copyrights 2000 The Seoul Times Company  ST Banner Exchange